RAPID MICRO BIOSYSTEMS, INC.

Join this Action
Practice Area:
Stock Symbol: RPID
Case Status: Investigations

Ademi LLP is investigating whether the proposed acquisition of Rapid Micro Biosystems (NASDAQ: RPID) by Merck, provides fair value to Rapid Micro Biosystems’ public shareholders and whether Rapid Micro Biosystems’ Board adequately protected shareholder interests in negotiating and approving the transaction.

What Is Ademi LLP Investigating?

  • The purchase price and whether it adequately reflects Rapid Micro Biosystems’ value and future prospects;
  • Substantial change-of-control benefits available to Rapid Micro Biosystems insiders in connection with the transaction;
  • Restrictions on competing transactions, including a significant termination penalty that may discourage another potential buyer from making a superior proposal; and
  • The conduct of Rapid Micro Biosystems’ Board of Directors in negotiating and approving the transaction and whether the Board fulfilled its duties to public shareholders.
Join this Action